The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:https://doi.org/10.1176/appi.ps.55.6.714

This study provided representative data about the attitudes and behaviors of psychiatrists with respect to obtaining informed consent for antipsychotic medications. A cross-sectional representative survey of 617 psychiatrists, stratified by age and gender, was conducted by using a self-report questionnaire. The response rate was 72 percent (N=427). Demographic characteristics did not correlate with whether the respondents disclosed information about the potential side effect of tardive dyskinesia, which is associated with antipsychotic medications. Respondents' attitudes toward informed consent were a strong predictor of whether they disclosed information about antipsychotic medications and the risk of tardive dyskinesia. A total of 263 respondents (78 percent) routinely disclosed information about tardive dyskinesia.